Originally spun-out of deCode Genetics in 2009, the following year Emerald Biostuctures a proetomics company) became part of Beyllium LLC and Medichem Research - all still remaining small and SBIR eligible. Emerald BioStructures performs protein crystallization services for a range of drug discovery organizations. The firm's fragment screening and fragment discovery services identify new chemical matter for modulating enzyme activity or protein-protein interactions. Emerald BioStructures' structural biology services informs medicinal chemists, strengthens intellectual property claims, and provides valuable insights that can be applied at any stage in the drug discovery pipeline.
